Patient‐reported outcomes in castration‐resistant prostate cancer with bone metastases treated with radium‐223 with or without olaparib
Cancer · 2026
DOI: 10.1002/cncr.70496 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Cancer, 2026. Verfasst von Rana R McKay und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Medicine, University of California San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: Radium, Prostatic Neoplasms, Castration-Resistant, Patient Reported Outcome Measures, Piperazines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIH HHS, Prostate Cancer Foundation.
Abstract (Originalsprache)
Background
The combination of olaparib plus radium‐223 improved progression‐free survival in patients with metastatic castration‐resistant prostate cancer with bone metastases (BM) in the multicenter, randomized, phase 2 COMRADE trial (NCT03317391). Here, the patient‐reported outcome (PRO) analysis of this trial is reported.
Methods
Patients were randomized 1:1 to olaparib plus radium‐223 (arm A) or radium‐223 alone (arm B). PROs were assessed via the Functional Assessment of Cancer Therapy–Prostate (FACT‐P) and Brief Pain Inventory (BPI) at baseline and every 12 weeks. Clinically meaningful changes were defined as a ≥10‐point change in FACT‐P total score and a ≥30% or ≥2‐point change in BPI score. Mixed‐effects analysis‐of‐covariance models assessed PRO changes with adjustment for baseline characteristics among patients with baseline and ≥1 postbaseline assessment within 24 weeks.
Results
Of 114 treated patients, 74 (65%) were evaluable (arm A, n = 40; arm B, n = 34). Baseline characteristics were balanced, with a median age of 70–72 years and Eastern Cooperative Oncology Group performance status of 1 in 60%–62%, prior docetaxel in 50%–55%, >20 BM in 45%–47%, and pain medication use in 60%–72% of patients. No significant differences in FACT‐P total score change was observed at Week 12 (−4.87; 95% CI, −13.4 to 3.62) or Week 24 (1.79; 95% CI, −8.28 to 11.9). BPI pain severity did not differ at Week 12 (0.44; 95% CI, −0.44 to 1.33) or Week 24 (−0.20; 95% CI, −1.32 to 0.93). Arm B showed greater improvement in BPI pain interference at Week 12 (1.09; 95% CI, 0.14 to 2.05), which was not sustained at Week 24.
Conclusions
The addition of olaparib to radium‐223 was not associated with significant detriment to PROs or pain, which supports the tolerability of this combination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Medicine, University of California San Diego, La Jolla, California, USA.
- Department of Urology, University of California San Diego, La Jolla, California, USA.
- Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California, USA.
- Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- Department of Internal Medicine, Ohio State University, Columbus, Ohio, USA.
- Department of Medicine, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA.
ORCID-Profile: Rana R McKay
Förderung
- NCI NIH HHS
- NIH HHS
- Prostate Cancer Foundation
- National Cancer Institute
- National Institutes of Health
Zitieren
APA
McKay, R. R., Xie, W., Ajmera, A., Araneta, A., Folefac, E., Hussain, A., Kyriakopoulos, C. E., Olson, A., Parikh, M., Parikh, R., Saraiya, B., & Shapiro, G. I. (2026). Patient‐reported outcomes in castration‐resistant prostate cancer with bone metastases treated with radium‐223 with or without olaparib. Cancer. https://doi.org/10.1002/cncr.70496
Vancouver
McKay RR, Xie W, Ajmera A, Araneta A, Folefac E, Hussain A, et al. Patient‐reported outcomes in castration‐resistant prostate cancer with bone metastases treated with radium‐223 with or without olaparib. Cancer. 2026. doi:10.1002/cncr.70496
BibTeX
@article{McKay2026,
author = {McKay, Rana R and Xie, Wanling and Ajmera, Archana and Araneta, Arlene and Folefac, Edmund and Hussain, Arif and Kyriakopoulos, Christos E and Olson, Adam and Parikh, Mamta and Parikh, Rahul and Saraiya, Biren and Shapiro, Geoffrey I},
title = {Patient‐reported outcomes in castration‐resistant prostate cancer with bone metastases treated with radium‐223 with or without olaparib},
journal = {Cancer},
year = {2026},
doi = {10.1002/cncr.70496}
}
EUVIMED